首页> 外文期刊>Journal of Vascular Diagnostics and Interventions >Ultrasound-guided percutaneous thrombin injection following iatrogenic femoral artery pseudoaneurysm: patient selection and perspectives
【24h】

Ultrasound-guided percutaneous thrombin injection following iatrogenic femoral artery pseudoaneurysm: patient selection and perspectives

机译:医源性股动脉假性动脉瘤的超声引导下经皮凝血酶注射:患者选择和观点

获取原文
           

摘要

Ultrasound-guided percutaneous thrombin injection (UGTI) following iatrogenic femoral artery pseudoaneurysms has been the standard of care as first-line treatment at many institutions since its initial description by Liau et al in 1997. UGTI underwent rapid adoption given its significant advantages to patients including shorter procedure times, decreased discomfort, lower rates of recurrence, and the avoidance of surgical intervention in appropriate cases. Despite the availability of less-invasive approaches, through numerous head-to-head studies, UGTI has demonstrated clear benefit over ultrasound-guided compression in the treatment of iatrogenic femoral artery pseudoaneurysms. Although newer interventions such as percutaneous coil embolization have attracted attention for their superior ability to manage those patients with high-level anticoagulation or allergies to thrombin, at this time they do not provide an equal alternative to thrombin injection. In this review, we focus on issues related to the selection of patients who benefit from UGTI for the treatment of iatrogenic pseudoaneurysms.
机译:自1997年Liau等人最初描述以来,医源性股动脉假性动脉瘤之后的超声引导经皮凝血酶注射(UGTI)已成为许多机构的一线治疗标准。由于其对包括:缩短手术时间,减少不适感,降低复发率,并在适当情况下避免手术干预。尽管采用了侵入性较小的方法,但通过大量的头对头研究,UGTI在医源性股动脉假性动脉瘤的治疗中已显示出明显优于超声引导压缩的优势。尽管较新的干预措施(如经皮线圈栓塞术)因其对那些对凝血酶有高水平抗凝或过敏反应的患者的超强治疗能力而引起了人们的关注,但目前,它们还不能提供与凝血酶注射相同的替代方法。在这篇综述中,我们重点关注与从UGTI中受益的医源性假性动脉瘤治疗患者的选择有关的问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号